There were 1,397 press releases posted in the last 24 hours and 228,663 in the last 365 days.
Biosimilars Market 2022 - Opportunities And Strategies – Global Forecast To 2031
The Business Research Company’s Biosimilars Market 2022 - Opportunities And Strategies – Global Forecast To 2031
LONDON, GREATER LONDON, UK, August 31, 2022 /EINPresswire.com/ -- High penetration of the biologics is expected to be a driver of market growth during this period. Pharmaceutical companies are shifting towards originator biologics and competitive biosimilar drug development. Pharma companies had focused on small molecules for decades, but the rate of innovation in that field has slowed dramatically, leading to the shift towards biologics. These research and development (R&D) activities have led to increasing success rates in clinical trials. R&D is being carried out by market leaders as they continuously strive to make breakthroughs in the form of new and effective biologics. This flow of originator biologics will provide the future substrate for biosimilar market growth. The market is expected to grow from $11.42 billion in 2021 to $25.98 billion in 2026 at a rate of 17.3%. The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59.55 billion in 2031.
Read more on the Global Biosimilars Market Report https://www.thebusinessresearchcompany.com/report/biosimilars-market
The increasing adoption and use of robotics and artificial intelligence (AI) are key trends gaining popularity in the biosimilars market. Artificial intelligence is intelligence demonstrated by machines and is highly versatile. Targeted applications of mobile robots are expected to help decrease the dependency on manual labor and associated costs of biomanufacturing. Robots help execute various routine operations such as material handling, waste handling, material transport, hazardous operations, autonomous operations, and challenging tasks such as precision machining. Furthermore, robots are being developed to be smarter less expensive, and more versatile.
Major players covered in the global biosimilars industry are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris.
Western Europe was the largest region in the global biosimilars market, accounting for 66.0% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the global biosimilars market will be Africa and Eastern Europe where growth will be at CAGRs of 117.0% and 60.1% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 53.854% and 53.851% respectively.
TBRC’s biosimilars market report is segmented by type into monoclonal antibodies, insulin, erythropoietin, granulocyte-colony stimulating factor, other hormones, others, by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, others.
Biosimilars Market 2022 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), And By Region, Opportunities And Strategies – Global Forecast To 2031 is one of a series of new reports from The Business Research Company that provides a biosimilars market overview, forecast biosimilars market size and growth for the whole market, biosimilars market segments, geographies, biosimilars market trends, biosimilars market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request for a Sample of the Global Biosimilars Market Report https://www.thebusinessresearchcompany.com/sample.aspx?id=6175&type=smp
Not what you were looking for? Here is a list of similar reports by The Business Research Company: Biosimilar Monoclonal Antibodies Global Market Report 2022 – By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab) – Market Size, Trends, And Global Forecast 2022-2026 https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report
Biosimilar Hormones Global Market Report 2022 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2022-2026 https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
Filgrastim Biosimilars Global Market Report 2022 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Organization) – Market Size, Trends, And Global Forecast 2022-2026 https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report
About The Business Research Company The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Contact Information: The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293 Email: info@tbrc.info
Check out our: TBRC Blog: http://blog.tbrc.info/ LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: http://blog.tbrc.info/
Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook Twitter LinkedIn
Market Research Products, Services, Solutions For Your Business - TBRC
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2022 Newsmatics Inc. dba EIN Presswire All Right Reserved.